je.st
news
Home
› Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
Highland Therapeutics Announces Initiation Of Pivotal Trial Of HLD-200 In Pediatric ADHD Patients
2015-08-05 07:56:18| drugdiscoveryonline Home Page
Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, recently announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), has initiated enrolment in a pivotal study to assess the safety and efficacy of HLD-200 – a next-generation formulation of methylphenidate – in children with Attention-Deficit/Hyperactivity Disorder (“ADHD”)
Tags: trial
patients
adhd
announces
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||